PL155712B1 - Method of obtaining novel crystalline form of cyclosporin - Google Patents

Method of obtaining novel crystalline form of cyclosporin

Info

Publication number: PL155712B1
Authority: PL; Poland
Prior art keywords: cyclosporin; medium; treatment; strong; agents
Prior art date: 1987-12-21

Application number

PL27656588A

Other languages

English (en)

Polish (pl)

Other versions

PL276565A1 (en

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-20

Publication date

1991-12-31

1988-12-20 Application filed by Sandoz Ag filed Critical Sandoz Ag

1989-08-21 Publication of PL276565A1 publication Critical patent/PL276565A1/xx

1991-12-31 Publication of PL155712B1 publication Critical patent/PL155712B1/pl

Links

108010036949 Cyclosporine Proteins 0.000 title claims description 99
229960001265 ciclosporin Drugs 0.000 title claims description 99
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims description 98
229930182912 cyclosporin Natural products 0.000 title claims description 98
229930105110 Cyclosporin A Natural products 0.000 title claims description 71
238000000034 method Methods 0.000 title claims description 36
239000013078 crystal Substances 0.000 claims description 33
239000000902 placebo Substances 0.000 claims description 20
229940068196 placebo Drugs 0.000 claims description 20
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
229920001223 polyethylene glycol Polymers 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 10
239000002202 Polyethylene glycol Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
229940100688 oral solution Drugs 0.000 claims description 6
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 claims description 3
238000002441 X-ray diffraction Methods 0.000 claims description 3
QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
239000002674 ointment Substances 0.000 claims 1
238000011282 treatment Methods 0.000 description 62
239000003795 chemical substances by application Substances 0.000 description 57
239000003814 drug Substances 0.000 description 41
239000002245 particle Substances 0.000 description 40
229940079593 drug Drugs 0.000 description 27
201000010099 disease Diseases 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
239000000203 mixture Substances 0.000 description 24
239000000047 product Substances 0.000 description 23
201000004681 Psoriasis Diseases 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
239000007924 injection Substances 0.000 description 19
238000002347 injection Methods 0.000 description 19
230000000699 topical effect Effects 0.000 description 18
238000012360 testing method Methods 0.000 description 15
238000002360 preparation method Methods 0.000 description 12
-1 see Fiedler Chemical class 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
239000004615 ingredient Substances 0.000 description 10
206010015150 Erythema Diseases 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000002253 acid Substances 0.000 description 8
231100000321 erythema Toxicity 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000013081 microcrystal Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000006071 cream Substances 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000004094 surface-active agent Substances 0.000 description 7
238000005809 transesterification reaction Methods 0.000 description 7
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
201000004624 Dermatitis Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000000600 sorbitol Substances 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
206010012438 Dermatitis atopic Diseases 0.000 description 5
206010012442 Dermatitis contact Diseases 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
208000003251 Pruritus Diseases 0.000 description 5
206010046851 Uveitis Diseases 0.000 description 5
201000008937 atopic dermatitis Diseases 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000011630 iodine Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
206010010741 Conjunctivitis Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
208000025747 Rheumatic disease Diseases 0.000 description 4
231100000360 alopecia Toxicity 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
208000030533 eye disease Diseases 0.000 description 4
239000008394 flocculating agent Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
150000002334 glycols Chemical class 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000007803 itching Effects 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000012453 solvate Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000008719 thickening Effects 0.000 description 4
239000003860 topical agent Substances 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010036941 Cyclosporins Proteins 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
206010040844 Skin exfoliation Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000010247 contact dermatitis Diseases 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000003925 fat Substances 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
206010023332 keratitis Diseases 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000010466 nut oil Substances 0.000 description 3
235000019488 nut oil Nutrition 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
229940068886 polyethylene glycol 300 Drugs 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
238000006748 scratching Methods 0.000 description 3
230000002393 scratching effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
OWZPCEFYPSAJFR-UHFFFAOYSA-N 2-(butan-2-yl)-4,6-dinitrophenol Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O OWZPCEFYPSAJFR-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
206010020649 Hyperkeratosis Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000001126 Keratosis Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000013019 agitation Methods 0.000 description 2
208000002029 allergic contact dermatitis Diseases 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000036576 dermal application Effects 0.000 description 2
230000035618 desquamation Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000003801 milling Methods 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000006911 nucleation Effects 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282988 Capreolus Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007764 Cataract subcapsular Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
208000001840 Dandruff Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
241001503951 Phoma Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000700141 Rotifera Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
208000002719 Substance-Induced Psychoses Diseases 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000270666 Testudines Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
208000007287 cheilitis Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000881 depressing effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
208000027993 eye symptom Diseases 0.000 description 1
238000005562 fading Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
239000012051 hydrophobic carrier Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
230000004140 ketosis Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000012263 liquid product Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
239000010450 olivine Substances 0.000 description 1
229910052609 olivine Inorganic materials 0.000 description 1
229940125702 ophthalmic agent Drugs 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
229940023569 palmate Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000036281 parasite infection Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
201000003725 primary thrombocytopenia Diseases 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
231100001028 renal lesion Toxicity 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000003091 serenic agent Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-M valproate Chemical compound CCCC(C([O-])=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-M 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008136 water-miscible vehicle Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

PL27656588A 1987-12-21 1988-12-20 Method of obtaining novel crystalline form of cyclosporin PL155712B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13623087A	1987-12-21	1987-12-21

Publications (2)

Publication Number	Publication Date
PL276565A1 PL276565A1 (en)	1989-08-21
PL155712B1 true PL155712B1 (en)	1991-12-31

Family

ID=22471933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL27656588A PL155712B1 (en)	1987-12-21	1988-12-20	Method of obtaining novel crystalline form of cyclosporin

Country Status (8)

Country	Link
CZ (1)	CZ279654B6 (de)
DD (1)	DD283404A5 (de)
PL (1)	PL155712B1 (de)
PT (1)	PT89279B (de)
RU (1)	RU2002754C1 (de)
SK (1)	SK278320B6 (de)
UA (1)	UA11244A1 (de)
ZA (1)	ZA889540B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
DE19613933A1 (de) *	1996-04-06	1997-10-09	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
SE9604341D0 (sv) *	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue

1988
- 1988-12-20 PL PL27656588A patent/PL155712B1/pl unknown
- 1988-12-20 DD DD32344488A patent/DD283404A5/de not_active IP Right Cessation
- 1988-12-20 CZ CS888474A patent/CZ279654B6/cs not_active IP Right Cessation
- 1988-12-20 PT PT8927988A patent/PT89279B/pt not_active IP Right Cessation
- 1988-12-20 SK SK8474-88A patent/SK278320B6/sk unknown
- 1988-12-21 RU SU4613289 patent/RU2002754C1/ru active
- 1988-12-21 ZA ZA889540A patent/ZA889540B/xx unknown
- 1988-12-21 UA UA4613289A patent/UA11244A1/uk unknown

Also Published As

Publication number	Publication date
RU2002754C1 (ru)	1993-11-15
SK847488A3 (en)	1996-10-02
CZ847488A3 (en)	1995-02-15
ZA889540B (en)	1990-08-29
SK278320B6 (en)	1996-10-02
PL276565A1 (en)	1989-08-21
CZ279654B6 (cs)	1995-05-17
DD283404A5 (de)	1990-10-10
UA11244A1 (uk)	1996-12-25
PT89279A (pt)	1989-12-29
PT89279B (pt)	1993-08-31

Publication	Publication Date	Title
KR100188305B1 (ko)	1999-06-01	신규의 시클로스포린 결정 형태, 이것의 제조 방법 및 이것을 함유한 약학 조성물 및 그 용도
DE60309433T2 (de)	2007-05-03	Pharmazeutische zusammensetzungen für proteasehemmer für hepatitis-c-virus
CN1096861C (zh)	2002-12-25	用5－α还原酶抑制剂治疗雄激素引起的脱发的方法
JPH02121929A (ja)	1990-05-09	シクロスポリン含有医薬組成物
NL195094C (nl)	2003-12-17	Farmaceutische preparaat dat opgelost cyclosporine bevat en werkwijze voor de bereiding daarvan.
JPH11512115A (ja)	1999-10-19	経口投与用製剤組成物
MXPA03003150A (es)	2003-07-14	Soluciones farmaceuticas de compuestos de modafinilo.
JPH07196512A (ja)	1995-08-01	医薬組成物
JPH0768130B2 (ja)	1995-07-26	微粒子化薬剤
JPH0840880A (ja)	1996-02-13	軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法
PL155712B1 (en)	1991-12-31	Method of obtaining novel crystalline form of cyclosporin
MXPA02003190A (es)	2002-09-30	Formulacion para portadores farmaceuticos.
DE102009033396A1 (de)	2011-01-20	Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
JP2002543209A (ja)	2002-12-17	抗酸化物ビタミンｂ６類似体
CZ20021433A3 (cs)	2002-08-14	Proléčivo na bázi 6-methoxy-2-naftyloctové kyseliny
JPH01168619A (ja)	1989-07-04	新規な酢酸クロルマジノン固形製剤
EP0652223A1 (de)	1995-05-10	3-Oxygermylpropionsäurepolymere
JP2516477B2 (ja)	1996-07-24	皮膚の血行不良に起因する疾患の治療剤
JPH0374330A (ja)	1991-03-28	脱髄疾患治療剤
JP2800412B2 (ja)	1998-09-21	免疫抑制作用増強剤
Kossard	1990	Blistering disorders and their differential diagnosis and management
HU212727B (en)	1996-10-28	Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component
WO2002009670A1 (en)	2002-02-07	Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same
JPH0459729A (ja)	1992-02-26	肝障害抑制剤
JPWO2001012198A1 (ja)	2003-03-04	心筋梗塞治療薬